Liver cancer, lung cancer, pancreatic cancer
Conditions
Interventions
Case series:Kanglaite Injection and Kanglaite Capsules
Sponsors
Tumor Hospital of Jiangsu Province, the First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Comply with the instructions of Kanglaite indications of lung cancer and liver cancer and pancreatic cancer; 2) It is expected that at least 2 cycles of patients can be completed; 3) Patients who were expected to survive for more than 3 months; 4) Previous use of traditional Chinese medicine in the treatment of cancer, a washout period of at least 7 days; 5) Patients who voluntarily joined the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1) Also received more than two kinds of anti-tumor traditional Chinese medicine in the treatment of patients (including KLT); 2) Participants are participating in other clinical trials of antitumor drugs; 3) Patients who did not sign the informed consent form; 4) Patients with severe disorder of fat metabolism (acute shock, acute pancreatitis, histopathological hyperlipidemia, and lipid nephrosis And other patients); 5) Serious abnormal liver function; 6) Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nutritional status score;safety;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate;Overall survival; | — |
Contacts
Public Contactshu yongqian
Tumor Hospital of Jiangsu Province
Outcome results
None listed